Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. [electronic resource]
Producer: 20000530Description: 609-16 p. digitalISSN:- 0003-987X
- Adult
- Animals
- Antineoplastic Agents -- metabolism
- Cell Differentiation
- Chromans -- metabolism
- DNA Primers
- Female
- Humans
- Keratinocytes -- cytology
- Ligands
- Male
- Mice
- Mice, SCID
- Psoriasis -- drug therapy
- RNA, Messenger -- metabolism
- Receptors, Cytoplasmic and Nuclear -- genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Skin Diseases -- drug therapy
- Thiazoles -- metabolism
- Thiazolidinediones
- Transcription Factors -- genetics
- Troglitazone
No physical items for this record
Publication Type: Case Reports; Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.